Rozrolimupab, symphobodies against rhesus D, for the potential prevention of hemolytic disease of the newborn and the treatment of idiopathic thrombocytopenic purpura

Current Opinion in Molecular Therapeutics

Volumn 12, Issue 6, 2010, Pages 734-740

  Stasi, Roberto ^a  

^a ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; POLYCLONAL ANTIBODY; RHESUS D ANTIGEN; ROZROLIMUPAB; SYM 001; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ARTICLE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG SCREENING; DRUG SYNTHESIS; DRUG TOLERANCE; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOGENICITY; MULTICENTER STUDY (TOPIC); NEWBORN HEMOLYTIC DISEASE; PATENT; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTIBODIES, MONOCLONAL; CLINICAL TRIALS AS TOPIC; ERYTHROBLASTOSIS, FETAL; ERYTHROCYTES; HUMANS; IMMUNOGLOBULIN G; INFANT, NEWBORN; ISOANTIBODIES; PROTEIN BINDING; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RECOMBINANT PROTEINS; RH-HR BLOOD-GROUP SYSTEM;

EID: 79952924019     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Research, technologies and applications in biodefense, Washington DC, USA. Haurum JS IDDB Meeting Report 2003 August 27-28
2. Antibodies and recombinant proteins-Wilbio Asia/Pacifc's second annual conference, Singapore. Greer F IDDB Meeting Report 2005 September 5-7
3. Biovitrum and Symphogen enter co-development and commercialization agreement for recombinant polyclonal antibodies for the treatment of certain Blood disorders. Symphogen A/S Press Release 2006 February 01
4. Symphogen and Biovitrum initiate phase 1 clinical trial with the frst recombinant polyclonal antibody to enter clinical evaluation. Symphogen A/S Press Release 2007 March 12
5. Drug development pipeline: Fatty acid-binding protein 4 inhibitors, Biovitrum, AMP protein kinase agonist (diabetes), Biovitrum and dual PPAR α/γ agonists (type II diabetes), Biovitrum. Biovitrum AB Company Communication 2008 May 07
6. Symphogen and Biovitrum have initiated a novel treatment study in autoimmune bleeding disorder (ITP) patients Symphogen A/S Press Release 2008 July 16
7. Biovitrum and Symphogen report positive clinical Results in novel Rh-immunization prevention project. Biovitrum AB; Symphogen A/S Press Release 2008 December 20
8. Sym001, the frst recombinant polyclonal rhesus-D-specifc antibody product, was safe and well-tolerated in a placebo-controlled randomized phase I trial. Hjelmstrom P, Hallen B, Lindenstroem E, Gyaw S Am Soc Hematol Ann Meet Exposition 2008 50 December 07 Abs 1987
9. A human anti-D monoclonal antibody selected for enhanced FcγRIII engagement clears RhD+ autologous red cells in human volunteers as effciently as polyclonal anti-D antibodies. Beliard R, Waegemans T, Notelet D, Massad L, Dhainaut F, Romeuf C, Guemas E, Haazen W, Bourel D, Teillaud JL, Prost JF Br J Haematol 2008 141 1 109-119 (Pubitemid 351347525) (Pubitemid 351347525)
10. Production of target-specifc recombinant human polyclonal antibodies in mammalian cells. Wiberg FC, Rasmussen SK, Frandsen TP, Rasmussen LK, Tengbjerg K, Coljee VW, Sharon J, Yang CY, Bregenholt S, Nielsen LS, Haurum JS et al Biotechnol Bioeng 2006 94 2 396-405 (Pubitemid 43799538) (Pubitemid 43799538)
11. Development of recombinant human polyclonal antibodies for the treatment of complex human diseases. Tolstrup AB, Frandsen TP, Bregenholt S Expert Opin Biol Ther 2006 6 9 905-912
12. Development of recombinant polyclonal antibodies. Haurum J Hum Antibodies 2007 16 1-2 35
13. Development of recombinant human polyclonal antibody Therapeutics. Haurum J J Biotechnol 2005 118 Suppl 1 S64
14. D epitope evaluation of the 25 rhesus-D-specifc IgG1 antibodies in rozrolimupab (Sym001), the frst recombinant polyclonal antibody product. Wiken M, Jensen AMV, Andersen PS, Flegel WA Haematologica-Hematol J 2009 94 Suppl 2 Abs 0178
15. Biovitrum: Interim report 1st April-30th June, 2009. Biovitrum AB Press Release 2009 July 23
16. Binding of the recombinant polyclonal anti-D product rozrolimupab (Sym001) and plasma-derived anti-D to RhD variants. Wiken M, Jensen AMV, Andersen PS, Flegel WA Haematologica-Hematol J 2009 94 Suppl 2 Abs 0188
17. Recombinant polyclonal antibodies: The next Generation of antibody Therapeutics? Haurum JS Drug Disc Today 2006 11 13-14 655-660
18. Isolation of human antibody repertoiRes with pReservation of the natural heavy and light chain pairing. Meijer PJ, Andersen PS, Haahr Hansen M, Steinaa L, Jensen A, Lantto J, Oleksiewicz MB, Tengbjerg K, Poulsen TR, Coljee VW, Bregenholt S et al J Mol Biol 2006 358 3 764-772
19. Single-batch production of recombinant human polyclonal antibodies. Nielsen LS, Baer A, Muller C, Gregersen K, Monster NT, Rasmussen SK, Weilguny D, Tolstrup AB Mol Biotechnol 2010 45 3 257-266
20. Idiopathic thrombocytopenic purpura: Current concepts in pathophysiology and management. Stasi R, Evangelista ML, Stipa E, Buccisano F, Venditti A, Amadori S Thromb Haemost 2008 99 1 4-13
21. Anti-D initially stimulates an Fc-dependent leukocyte oxidative burst and subsequently suppResses erythrophagocytosis via interleukin-1 receptor antagonist. Coopamah MD, Freedman J, Semple JW Blood 2003 102 8 2862-2867 (Pubitemid 37248858) (Pubitemid 37248858)
22. Disseminated intravascular coagulation associated with acute hemoglobinemia or hemoglobinuria following Rh (D) immune globulin intravenous administration for immune thrombocytopenic purpura. Gaines AR Blood 2005 106 5 1532-1537 (Pubitemid 41208562) (Pubitemid 41208562)
23. The prevention and management of haemolytic disease of the newborn. Contreras M, de Silva M J R Soc Med 1994 87 5 256-258 (Pubitemid 24175092) (Pubitemid 24175092)
24. Mechanisms of anti-D action in the prevention of hemolytic disease of the fetus and newborn. Brinc D, Lazarus AH Hematology Am Soc Hematol Educ Program 2009 185-191
25. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Kenny-Walsh E N Engl J Med 1999 340 16 1228-1233 (Pubitemid 29181642) (Pubitemid 29181642)
26. Severe hemolysis following administration of Rh (D) immune globulin in an ITP patient associated with anti-C. Schwartz J, Spitalnik S, Grima KM Blood 2006 107 6 2585 (Pubitemid 43345585) (Pubitemid 43345585)
27. WinRho SDF (Rh(D) immune globulin intravenous (human)): Risk of intravascular hemolysis. US Food and Drug Administration FDA MEDWATCH 2010
28. Quantifcation of IgG anti-D bound to D-positive red cells infused into D-negative subjects after intramuscular injection of monoclonal anti-D. Kumpel BM, Judson PA Transfus Med 1995 5 2 105-112
29. Clearance of red cells by monoclonal IgG3 anti-D in vivo is affected by the VF polymorphism of FcγRIIIa (CD16). Kumpel BM, De Haas M, Koene HR, Van De Winkel JG, Goodrick MJ Clin Exp Immunol 2003 132 1 81-86 (Pubitemid 36418909) (Pubitemid 36418909)
30. A single recombinant anti-RhD IgG prevents RhD immunization: Association of RhD-positive red Blood cell clearance rate with polymorphisms in the FcγRIIA and FcγIIIA Genes. Miescher S, Spycher MO, Amstutz H, De Haas M, Kleijer M, Kalus UJ, Radtke H, Hubsch A, AndResen I, Martin RM, Bichler J Blood 2004 103 11 4028-4035 (Pubitemid 38685340) (Pubitemid 38685340)
31. Lessons learnt from many years of experience using anti-D in humans for prevention of RhD immunization and haemolytic disease of the fetus and newborn. Kumpel BM Clin Exp Immunol 2008 154 1 1-5
32. The management of hemolytic disease in the fetus and newborn. Bowman J Semin Perinatol 1997 21 1 39-44 (Pubitemid 27247325) (Pubitemid 27247325)
33. Identifcation and production of recombinant human polyclonal antibody drugs refecting the natural human antibody diversity. Bregenholt S, Jensen A Plasma Product Biotechnol Meet 2005 4 May 9-12 Abs 201
34. Symphogen and Swedish Orphan Biovitrum receive US orphan drug designation for rozrolimupab in ITP. Symphogen A/S; Swedish Orphan Biovitrum Press Release 2010 October 06
35. IV immunoglobulin Therapy for infectious diseases. No authors listed Drug Ther Bull 2010 48 5 57-60
36. Rozrolimupab. The United States Pharmacopeial Convention Pharm Forum 2009 35 5 21
37. International standard for minimum potency of anti-D Blood grouping reagents. World Health Organization WHO TECH REP SER 2005 WHO/BS/04.2000 Rev. 1
38. Rhophylac Rh (D) immune globulin intravenous (Human) 1500 IU (300 mcg). The US Food and Drug Administration FDA Drug Bull 2007
39. Single-batch production of recombinant human polyclonal antibodies. Nielsen LS, Baer A, Muller C, Gregersen K, Monster NT, Rasmussen SK, Weilguny D, Tolstrup AB Mol Biotechnol 2010 45 3 257-266
40. The incidence of idiopathic thrombocytopenic purpura in adults increases with age. Federiksen H, Schmidt K Blood 1999 94 9 909-913 (Pubitemid 29361821) (Pubitemid 29361821)
41. Clinically signifcant newly pResenting autoimmune thrombocytopenic purpura in adults: A prospective study of a population-based cohort of 245 patients. Neylon AJ, Saunders PW, Howard MR, Proctor SJ, Taylor PR Br J Haematol 2003 122 6 966-974 (Pubitemid 37174618) (Pubitemid 37174618)
42. Epitope specifcity and isotype of monoclonal anti-D antibodies dictate their ability to inhibit phagocytosis of opsonized platelets. Kjaersgaard M, Aslam R, Kim M, Speck ER, Freedman J, Stewart DI, Wiersma EJ, Semple JW Blood 2007 110 4 1359-1361 (Pubitemid 47281437) (Pubitemid 47281437)
43. Synergistic effect of blending IgG1 and IgG3 monoclonal anti-D in promoting the metabolic Response of monocytes to sensitized red cells. Hadley AG, Kumpel BM Immunology 1989 67 4 550-552 (Pubitemid 19203699) (Pubitemid 19203699)
44. Evaluation of a panel of human monoclonal antibodies to D and exploration of the synergistic effects of blending IgG1 and IgG3 antibodies on their in vitro biologic function. Armstrong-Fisher SS, Carter MC, Downing I, Fraser RH, Inglis GE, Allan EK, Mackie A, Prowse CV, Templeton JG, Thorpe SJ, Urbaniak SJ Transfusion 1999 39 9 1005-1012 (Pubitemid 29439798) (Pubitemid 29439798)
45. Functional in vitro studies of recombinant human immunoglobulin G and immunoglobulin A anti-D. Nielsen LK, Green TH, Norderhaug L, Sandlie I, Dziegiel MH Transfusion 2007 47 2 306-315 (Pubitemid 46146566) (Pubitemid 46146566)